As an automotive company in constant evolution, Renault Group is profoundly redefining the design of its vehicles, by rethinking how they are conceived. In an exclusive series entitled “Design Talks”, ...

-- ( BUSINESS WIRE )--Keysight Technologies, Inc. (NYSE: KEYS): ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Inovio Pharmaceuticals ( INO -3.64%) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

NGN-401 uses an adeno-associated virus serotype 9 vector to deliver a full-length functional MECP2 ... The company also said it plans to provide an update in the first half of 2025 on the design of a ...

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one <a target=_blank href= ...

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... was $19.0 million for the quarter ended September 30, 2024, compared to $9.4 million for the same ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, and welcome to Fractyl Health’s Third Quarter Financial Results and Business Updates Call. As a reminder, this conference ...